Position of the Transparency Council – Jardiance (empagliflozin)
At its meeting on 16 December 2024, the Transparency Council adopted position No. 145/2024 on the evaluation of the drug Jardiance (empagliflozin) in the indication for chronic kidney disease in adult patients